Organon CFO receives new RSU grants, exercises awards
Organon & Co. Chief Financial Officer Matthew M. Walsh reported a series of equity compensation transactions in Organon common stock.
Rhea-AI Filing Summary
Organon & Co. Chief Financial Officer Matthew M. Walsh reported a series of equity compensation transactions in Organon common stock. On March 31, 2026, he was granted 321,368 restricted stock units (RSUs) and a separate grant of 83,472 RSUs, each RSU representing a contingent right to one share of common stock. These RSUs will vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. On the same date, portions of earlier RSU awards granted in 2023 and 2025 vested and were exercised into common stock, while 4,127 and 7,380 shares were withheld at $5.70 per share to cover tax obligations. Following these transactions, Walsh directly holds 212,746 shares of Organon common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
33,593 shares exercised/converted
Exercise
8 txns
Insider
WALSH MATTHEW M
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 321,368 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Units | 83,472 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units | 12,047 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units | 21,546 | $0.00 | $0.00 |
| Exercise | Common Stock | 12,047 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 4,127 | $5.70 | $24K |
| Exercise | Common Stock | 21,546 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 7,380 | $5.70 | $42K |
Holdings After Transaction:
Restricted Stock Units — 447,934 contracts (Direct);
Common Stock — 212,746 shares (Direct)
Footnotes (6)
- F1. The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
- F2. On March 31, 2026, the Reporting Person was granted 321,368 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
- F3. On March 31, 2026, the Reporting Person was granted 83,472 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
- F4. Each RSU represents a contingent right to receive one share of Organon common stock.
- F5. On March 31, 2023, the Reporting Person was granted 36,139 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.
- F6. On March 31, 2025, the Reporting Person was granted 64,640 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.
Key Figures
New RSU grant 1: 321,368 RSUs
New RSU grant 2: 83,472 RSUs
2023 RSU grant size: 36,139 RSUs
+5 more
8 metrics
New RSU grant 1
321,368 RSUs
Granted March 31, 2026; vests 2027–2029 in three equal installments
New RSU grant 2
83,472 RSUs
Granted March 31, 2026; vests 2027–2029 in three equal installments
2023 RSU grant size
36,139 RSUs
Granted March 31, 2023; remaining one-third vested March 31, 2026
2025 RSU grant size
64,640 RSUs
Granted March 31, 2025; one-third vested March 31, 2026
Tax-withheld shares
11,507 shares
4,127 and 7,380 common shares withheld at $5.70 for taxes
Common shares held
212,746 shares
Direct Organon common stock holdings after March 31, 2026 transactions
Exercise shares
33,593 shares
Common shares acquired via derivative exercises on March 31, 2026
Reference share price
$5.70 per share
Closing price used for tax-withholding dispositions on March 30, 2026
Key Terms
Restricted Stock Units, tax-withholding disposition, exercise or conversion of derivative security, contingent right, +1 more
5 terms
Restricted Stock Units financial
"The price is the closing market price of Organon & Co. common stock ... under which the Restricted Stock Units ("RSU") were awarded."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax-withholding disposition financial
"Payment of exercise price or tax liability by delivering securities"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
contingent right financial
"Each RSU represents a contingent right to receive one share of Organon common stock."
derivative security financial
"transaction_type: "derivative" and transaction_action: "derivative exercise/conversion""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
What did Organon (OGN) CFO Matthew Walsh report in this Form 4?
Organon CFO Matthew Walsh reported new equity awards and related share movements. He received large RSU grants and saw earlier RSUs vest into common stock, with some shares withheld to cover tax obligations as part of standard equity compensation.
How many new restricted stock units did the Organon (OGN) CFO receive?
Walsh received two new RSU grants totaling 404,840 RSUs (321,368 and 83,472). Each RSU represents a contingent right to one share of Organon common stock, subject to future vesting over a defined three-year schedule beginning in 2027.
When will Matthew Walsh’s new Organon (OGN) RSU grants vest?
Both RSU grants vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Vesting means Walsh earns the right to receive common shares, subject to the plan’s service and other applicable conditions.
What prior Organon (OGN) RSU grants vested in this Form 4?
RSUs granted on March 31, 2023 and March 31, 2025 partially vested. One-third of a 36,139-unit 2023 grant vested on March 31, 2026, and one-third of a 64,640-unit 2025 grant vested the same day, converting into Organon common shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
